TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that the company has appointed Kurt Azarbarzin to its board of directors. Mr. Azarbarzin will replace vacating TELA Bio director Paul Touhey.

“We are pleased to welcome such an accomplished and successful business strategist to our board of directors,” said Antony Koblish, president and chief executive officer of TELA Bio. “Mr. Azarbarzin’s experience in developing and commercializing medical devices across a range of markets will be invaluable to our company as we work to expand patient access to OviTex RBSs in hospitals around the world. On behalf of the management team and the board of directors, I would also like to thank Mr. Touhey for playing an instrumental role in the growth and development of TELA Bio.”

Mr. Azarbarzin currently serves as chief technology officer of CONMED Corporation where he leads research and development across all subsidiaries and business units. He was previously founder and chief executive officer of SurgiQuest, Inc., a medical device company focused on minimally invasive surgery that was acquired by CONMED Corporation in January 2016. Mr. Azarbarzin is a member of the executive board at Center for Biomedical Innovation and technology at Yale. He was also the founder and owner of KLM Consulting and served multiple roles in the U.S. surgical division of Tyco Healthcare including global vice president of research and development. Mr. Azarbarzin earned a Bachelor of Science from the University of Bridgeport and completed advanced graduate studies in mechanical design at Bridgeport Engineering Institute and manufacturing engineering at Bradley University.

“I look forward to working with a leadership team that has built a truly innovative and disruptive surgical reconstruction company,” said Mr. Azarbarzin. “TELA Bio has experienced significant market expansion this year while reporting initial results from a post-market study, securing strategic investment agreements and announcing plans for a European commercial launch. The company is extremely well-positioned for continued success as more hospital administrators, surgeons and patients learn about the clinical results and economic benefits that are being achieved with OviTex RBSs.”

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here